See more : Cathay General Bancorp (CATY) Income Statement Analysis – Financial Results
Complete financial analysis of Talphera, Inc. (TLPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Talphera, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- InnoCare Pharma Limited (9969.HK) Income Statement Analysis – Financial Results
- Retal Urban Development Company (4322.SR) Income Statement Analysis – Financial Results
- USERJOY Technology Co.,Ltd. (3546.TWO) Income Statement Analysis – Financial Results
- Recticel SA/NV (RECT.BR) Income Statement Analysis – Financial Results
- PT Wismilak Inti Makmur Tbk (WIIM.JK) Income Statement Analysis – Financial Results
Talphera, Inc. (TLPH)
About Talphera, Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 651.00K | 1.77M | 2.82M | 5.42M | 2.29M | 2.15M | 8.00M | 17.36M | 19.26M | 5.22M | 29.50M | 2.39M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.55M | 2.59M | 3.75M | 6.03M | 6.81M | 3.98M | 10.66M | 12.32M | 24.26M | 24.52M | 26.29M | 605.00K | 0.00 | 479.00K | 481.00K | 383.00K | 216.00K |
| Gross Profit | -4.90M | -820.00K | -935.00K | -616.00K | -4.52M | -1.83M | -2.66M | 5.04M | -5.00M | -19.30M | 3.21M | 1.79M | 1.07M | -479.00K | -481.00K | -383.00K | -216.00K |
| Gross Profit Ratio | -751.92% | -46.30% | -33.18% | -11.37% | -197.34% | -84.84% | -33.32% | 29.05% | -25.93% | -370.00% | 10.88% | 74.73% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.55M | 3.34M | 4.10M | 4.02M | 4.66M | 13.14M | 19.41M | 21.40M | 22.49M | 24.52M | 26.29M | 24.91M | 13.62M | 8.19M | 15.50M | 18.33M | 8.21M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 43.93M | 20.27M | 0.00 | 15.60M | 14.20M | 18.35M | 9.88M | 7.20M | 6.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 1.10M | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.99M | 17.01M | 30.94M | 36.33M | 45.03M | 20.77M | 16.61M | 15.60M | 14.20M | 18.35M | 9.88M | 7.20M | 6.80M | 3.51M | 3.05M | 1.98M | 1.87M |
| Other Expenses | 0.00 | 84.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.54M | 20.35M | 35.03M | 40.35M | 49.69M | 33.90M | 36.02M | 37.00M | 13.32M | 11.41M | 25.15M | 32.11M | 20.42M | 11.71M | 18.55M | 20.31M | 10.08M |
| Cost & Expenses | 17.54M | 20.35M | 38.78M | 46.38M | 56.49M | 37.88M | 46.68M | 49.31M | 37.58M | 35.93M | 51.44M | 32.11M | 20.42M | 12.19M | 19.03M | 20.69M | 10.29M |
| Interest Income | 6.74M | 1.50M | 3.16M | 3.89M | 1.28M | 11.42M | 13.83M | 12.00M | 5.32M | 2.64M | 1.49M | 0.00 | 1.56M | 4.00K | 33.00K | 484.00K | 687.00K |
| Interest Expense | 134.00K | 1.12M | 2.29M | 3.31M | 2.54M | 12.56M | 14.04M | 12.15M | 5.41M | 2.64M | 16.76M | 3.65M | 2.31M | 1.40M | 1.24M | 404.00K | 25.00K |
| Depreciation & Amortization | 311.00K | 1.65M | 1.97M | 1.85M | 1.67M | 575.00K | 1.74M | 2.05M | 1.98M | 866.00K | 593.00K | 605.00K | 513.00K | 479.00K | 481.00K | 383.00K | 216.00K |
| EBITDA | -9.84M | -17.20M | -30.83M | -35.22M | -49.03M | -34.01M | -36.43M | -28.99M | -16.25M | -29.85M | -6.07M | -29.11M | -17.28M | -12.47M | -18.40M | -19.88M | -9.39M |
| EBITDA Ratio | -1,511.83% | -971.37% | -1,094.04% | -650.24% | -2,295.19% | -1,634.22% | -462.01% | -172.29% | -89.36% | -705.06% | -20.59% | -1,215.87% | -1,611.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.89M | -25.30M | -35.97M | -40.96M | -54.21M | -35.73M | -38.68M | -31.96M | -19.20M | -37.65M | -6.67M | -29.71M | -19.35M | -12.19M | -19.03M | -20.69M | -10.29M |
| Operating Income Ratio | -2,594.32% | -1,428.57% | -1,276.26% | -756.33% | -2,368.06% | -1,660.95% | -483.83% | -184.12% | -99.66% | -721.66% | -22.60% | -1,241.14% | -1,805.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.60M | 84.44M | 871.00K | 588.00K | 968.00K | -11.42M | -13.53M | -11.23M | -4.44M | 4.30M | -16.76M | -3.65M | -749.00K | -2.16M | -1.09M | 28.00K | 661.00K |
| Income Before Tax | -10.29M | 59.14M | -35.09M | -40.38M | -53.24M | -47.15M | -52.21M | -43.19M | -23.64M | -33.35M | -23.43M | -33.36M | -20.10M | -14.34M | -20.12M | -20.66M | -9.63M |
| Income Before Tax Ratio | -1,580.18% | 3,339.24% | -1,245.35% | -745.48% | -2,325.78% | -2,191.86% | -653.02% | -248.84% | -122.72% | -639.31% | -79.40% | -1,393.61% | -1,875.09% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.00K | 5.00K | 4.00K | 3.00K | 2.00K | -701.00K | -34.00K | 760.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -18.40M | 47.76M | -35.10M | -40.38M | -53.24M | -47.15M | -51.51M | -43.16M | -24.40M | -33.35M | -23.43M | -33.36M | -20.10M | -14.34M | -20.12M | -20.66M | -9.63M |
| Net Income Ratio | -2,825.96% | 2,696.50% | -1,245.53% | -745.55% | -2,325.91% | -2,191.96% | -644.25% | -248.64% | -126.66% | -639.31% | -79.40% | -1,393.61% | -1,875.09% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.29 | 5.73 | -5.86 | -9.47 | -13.45 | -16.14 | -21.97 | -19.05 | -11.93 | -18.20 | -11.80 | -30.16 | -23.18 | -13.95 | -19.56 | -20.09 | -9.36 |
| EPS Diluted | -1.29 | 5.72 | -5.86 | -9.47 | -13.45 | -16.14 | -21.97 | -19.05 | -10.97 | -15.05 | -11.79 | -30.16 | -23.18 | -13.95 | -19.56 | -20.09 | -9.36 |
| Weighted Avg Shares Out | 14.26M | 7.41M | 5.99M | 4.26M | 3.96M | 2.92M | 2.34M | 2.27M | 2.05M | 1.83M | 1.99M | 1.11M | 867.24K | 1.03M | 1.03M | 1.03M | 1.03M |
| Weighted Avg Shares Out (Dil) | 14.26M | 7.41M | 5.99M | 4.26M | 3.96M | 2.92M | 2.34M | 2.27M | 2.22M | 2.22M | 1.99M | 1.11M | 867.24K | 1.03M | 1.03M | 1.03M | 1.03M |
Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - Chief Medical Officer Conference Call Participants James Molloy - Alliance Global Partners...
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast...
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
SAN MATEO, Calif. , Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third...
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a...
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
SAN MATEO, Calif. , Sept. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in...
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured over the first 24 hours, with patients...
Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Founder and Chief Medical Officer Conference Call Participants...
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites Cash and investments at June...
Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024
SAN MATEO, Calif. , Aug. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second...
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif. , May 20, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors...
Source: https://incomestatements.info
Category: Stock Reports